FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

19 letters match. Newest first.

  1. Peak Performance Peptides

    Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.

    High risk
  2. Royal Peptides LLC

    FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.

    High risk
  3. NuScience Peptides LLC

    FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.

    High risk
  4. Peptide Partners LLC

    Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.

    High risk
  5. TXP Innovations LLC dba Tex Peptides

    FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.

    High risk
  6. Gram Peptides

    Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.

    High risk
  7. Prime Sciences

    Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.

    High risk
  8. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  9. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  10. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  11. GenLabMeds

    GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.

    High risk
  12. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  13. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  14. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  15. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  16. Prime Vitality, Inc. dba Prime Peptides

    FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.

    High risk
  17. Swisschems

    Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.

    High risk
  18. Xcel Research LLC

    FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.

    High risk
  19. Summit Research Peptides

    FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.

    High risk